These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22624467)

  • 61. Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine.
    Crank MC; Mascola JR; Graham BS
    J Infect Dis; 2019 Apr; 219(Suppl_1):S107-S109. PubMed ID: 30715413
    [No Abstract]   [Full Text] [Related]  

  • 62. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
    Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
    Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prediction of epitopes in hemagglutinin and neuraminidase proteins of influenza A virus H5N1 strain: a clue for diagnostic and vaccine development.
    Somvanshi P; Singh V; Seth PK
    OMICS; 2008 Mar; 12(1):61-9. PubMed ID: 18266559
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Soluble recombinant influenza vaccines.
    Fiers W; Neirynck S; Deroo T; Saelens X; Jou WM
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1961-3. PubMed ID: 11779398
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase].
    Du J; Liu M; Liu C; Yang T; Li H
    Wei Sheng Wu Xue Bao; 2009 Jun; 49(6):813-9. PubMed ID: 19673419
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The molecular basis of antigenic variation in influenza virus.
    Air GM; Laver WG
    Adv Virus Res; 1986; 31():53-102. PubMed ID: 2428216
    [No Abstract]   [Full Text] [Related]  

  • 68. A "universal" human influenza A vaccine.
    Fiers W; De Filette M; Birkett A; Neirynck S; Min Jou W
    Virus Res; 2004 Jul; 103(1-2):173-6. PubMed ID: 15163506
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Live bivalent vaccine for parainfluenza and influenza virus infections.
    Maeda Y; Hatta M; Takada A; Watanabe T; Goto H; Neumann G; Kawaoka Y
    J Virol; 2005 Jun; 79(11):6674-9. PubMed ID: 15890905
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation.
    Farahmand B; Taheri N; Shokouhi H; Soleimanjahi H; Fotouhi F
    Virus Genes; 2019 Feb; 55(1):22-32. PubMed ID: 30382564
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Beating the flu in a single shot.
    Hellemans A
    Sci Am; 2008 Jun; 298(6):104, 106-7. PubMed ID: 18642549
    [No Abstract]   [Full Text] [Related]  

  • 72. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
    Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B
    J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular mechanisms of variation in influenza viruses.
    Webster RG; Laver WG; Air GM; Schild GC
    Nature; 1982 Mar; 296(5853):115-21. PubMed ID: 6174870
    [No Abstract]   [Full Text] [Related]  

  • 74. Viva la revolución: rethinking influenza a virus antigenic drift.
    Yewdell JW
    Curr Opin Virol; 2011 Sep; 1(3):177-83. PubMed ID: 22034587
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immune responses to highly conserved influenza A virus matrix 1 peptides.
    Lohia N; Baranwal M
    Microbiol Immunol; 2017 Jun; 61(6):225-231. PubMed ID: 28429374
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability.
    Tan PT; Khan AM; August JT
    Hum Vaccin; 2011 Apr; 7(4):402-9. PubMed ID: 21471731
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Using reverse genetics method for developing recombinant strains of influenza viruses acceptable for use as live attenuated vaccines].
    Merkulov VA; Lebedev VN; Plekhanova TM; Maksimov VA; Korovkin SA; Mironov AN
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (2):111-7. PubMed ID: 19462520
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Developments of subunit and VLP vaccines against influenza A virus.
    Deng MP; Hu ZH; Wang HL; Deng F
    Virol Sin; 2012 Jun; 27(3):145-53. PubMed ID: 22684468
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem.
    Andrews SF; Graham BS; Mascola JR; McDermott AB
    Cold Spring Harb Perspect Biol; 2018 Jul; 10(7):. PubMed ID: 28663207
    [TBL] [Abstract][Full Text] [Related]  

  • 80. From the National Institutes of Health. Summary of a meeting on the origin of pandemic influenza viruses.
    Laver WG; Webster RG; Chu CM
    J Infect Dis; 1984 Jan; 149(1):108-15. PubMed ID: 6198405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.